Downregulation of HDGF inhibits the tumorigenesis of bladder cancer cells by inactivating the PI3K-AKT signaling pathway

References

• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–E386. doi:10.1002/ijc.2921025220842
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• Jiang B, Hailong S, Yuan J, et al. Identification of oncogenic long noncoding RNA SNHG12 and DUXAP8 in human bladder cancer through a comprehensive profiling analysis. Biomed Pharmacother. 2018;108:500–507. doi:10.1016/j.biopha.2018.09.02530243082
   PubMed Web of Science ®Google Scholar
• Karsh L, Shore N, Soloway M, et al. Double-blind, randomized, placebo-controlled studies evaluating apaziquone (E09, Qapzola) intravesical instillation post transurethral resection of bladder tumors for the treatment of low-risk non-muscle invasive bladder cancer. Bladder Cancer. 2018;4(3):293–301. doi:10.3233/BLC-18016630112440
   PubMed Web of Science ®Google Scholar
• Goodspeed A, Jean A, Theodorescu D, et al. A gene expression signature predicts bladder cancer cell line sensitivity to EGFR inhibition. Bladder Cancer. 2018;4(3):269–282. doi:10.3233/BLC-17016130112438
   PubMed Web of Science ®Google Scholar
• Siddiqui MR, Grant C, Sanford T, et al. Current clinical trials in non-muscle invasive bladder cancer. Urol Oncol. 2017;35(8):516–527. doi:10.1016/j.urolonc.2017.06.04328778250
   PubMed Web of Science ®Google Scholar
• Vashistha V, Quinn DI, Dorff TB, et al. Current and recent clinical trials for perioperative systemic therapy for muscle invasive bladder cancer: a systematic review. BMC Cancer. 2014;14:966. doi:10.1186/1471-2407-14-96625515347
   PubMed Web of Science ®Google Scholar
• Chen M, Lv JM, Ye JQ, et al. Disruption of serine/threonine protein phosphatase 5 inhibits tumorigenesis of urinary bladder cancer cells. Int J Oncol. 2017;51(1):39–48. doi:10.3892/ijo.2017.399728534961
   PubMed Web of Science ®Google Scholar
• Nakamura H, Izumoto Y, Kambe H, et al. Molecular cloning of complementary DNA for a novel human hepatoma-derived growth factor. Its homology with high mobility group-1 protein. J Biol Chem. 1994;269(40):25143–25149.7929202
   PubMed Web of Science ®Google Scholar
• Nakamura H, Kambe H, Egawa T, et al. Partial purification and characterization of human hepatoma-derived growth factor. Clin Chim Acta. 1989;183(3):273–284. doi:10.1016/0009-8981(89)90361-62553304
   PubMed Web of Science ®Google Scholar
• Gijsbers R, Vets S, de Rijck J, et al. Role of the PWWP domain of lens epithelium-derived growth factor (LEDGF)/p75 cofactor in lentiviral integration targeting. J Biol Chem. 2011;286(48):41812–41825. doi:10.1074/jbc.M111.25571121987578
   PubMed Web of Science ®Google Scholar
• Kishima Y, Yamamoto H, Izumoto Y, et al. Hepatoma-derived growth factor stimulates cell growth after translocation to the nucleus by nuclear localization signals. J Biol Chem. 2002;277(12):10315–10322. doi:10.1074/jbc.M11112220011751870
   PubMed Web of Science ®Google Scholar
• Chen Z, Qiu S, Lu X. The expression and clinical significance of HDGF in osteosarcoma. Onco Targets Ther. 2015;8:2509–2517. doi:10.2147/OTT.S9170826392778
   PubMed Web of Science ®Google Scholar
• Zhang J, Ren H, Yuan P, et al. Down-regulation of hepatoma-derived growth factor inhibits anchorage-independent growth and invasion of non-small cell lung cancer cells. Cancer Res. 2006;66(1):18–23. doi:10.1158/0008-5472.CAN-04-390516397209
   PubMed Web of Science ®Google Scholar
• Chang KC, Tai MH, Lin JW, et al. Hepatoma-derived growth factor is a novel prognostic factor for gastrointestinal stromal tumors. Int J Cancer. 2007;121(5):1059–1065. doi:10.1002/ijc.2280317487837
   PubMed Web of Science ®Google Scholar
• Uyama H, Tomita Y, Nakamura H, et al. Hepatoma-derived growth factor is a novel prognostic factor for patients with pancreatic cancer. Clin Cancer Res. 2006;12(20 Pt 1):6043–6048. doi:10.1158/1078-0432.CCR-06-106417062679
   PubMed Web of Science ®Google Scholar
• Yamamoto S, Tomita Y, Hoshida Y, et al. Expression of hepatoma-derived growth factor is correlated with lymph node metastasis and prognosis of gastric carcinoma. Clin Cancer Res. 2006;12(1):117–122. doi:10.1158/1078-0432.CCR-05-134716397032
   PubMed Web of Science ®Google Scholar
• Uhlen M, Oksvold P, Fagerberg L, et al. Towards a knowledge-based human protein atlas. Nat Biotechnol. 2010;28(12):1248–1250. doi:10.1038/nbt1210-124821139605
   PubMed Web of Science ®Google Scholar
• Hu R, Wang MQ, Niu WB, et al. SKA3 promotes cell proliferation and migration in cervical cancer by activating the PI3K/Akt signaling pathway. Cancer Cell Int. 2018;18:183. doi:10.1186/s12935-018-0670-430459531
   PubMed Web of Science ®Google Scholar
• Liu C, Wang L, Jiang Q, et al. Hepatoma-derived growth factor and DDX5 promote carcinogenesis and progression of endometrial cancer by activating beta-catenin. Front Oncol. 2019;9:211. doi:10.3389/fonc.2019.0021131032220
   PubMed Web of Science ®Google Scholar
• Wang MJ, Zhang H, Li J, et al. microRNA-98 inhibits the proliferation, invasion, migration and promotes apoptosis of breast cancer cells by binding to HMGA2. Biosci Rep. 2018;38(5). doi: 10.1042/BSR20180571.
   Google Scholar
• Martinez Rodriguez RH, Buisan Rueda O, Ibarz L. Bladder cancer: present and future. Med Clin (Barc). 2017;149(10):449–455. doi:10.1016/j.medcli.2017.06.00928736063
   PubMed Web of Science ®Google Scholar
• van Lingen AV, Witjes JA. Current intravesical therapy for non-muscle invasive bladder cancer. Expert Opin Biol Ther. 2013;13(10):1371–1385. doi:10.1517/14712598.2013.82442123957696
   PubMed Web of Science ®Google Scholar
• Tian DW, Liu SL, Jiang LM, et al. RAB38 promotes bladder cancer growth by promoting cell proliferation and motility. World J Urol. 2018. doi:10.1007/s00345-018-2596-9
   Web of Science ®Google Scholar
• la Rosa H-D, Acker A,M, Kumar RA, et al. Epigenetics application in the diagnosis and treatment of bladder cancer. Can J Urol. 2015;22(5):7947–7951.26432963
   PubMed Web of Science ®Google Scholar
• Bao C, Wang J, Ma W, et al. HDGF: a novel jack-of-all-trades in cancer. Future Oncol. 2014;10(16):2675–2685. doi:10.2217/fon.14.19425236340
   PubMed Web of Science ®Google Scholar
• Min X, Wen J, Zhao L, et al. Role of hepatoma-derived growth factor in promoting de novo lipogenesis and tumorigenesis in hepatocellular carcinoma. Mol Oncol. 2018;12(9):1480–1497. doi:10.1002/1878-0261.1235730004626
   PubMed Web of Science ®Google Scholar
• Manilla P, Rebello T, Afable C, et al. Regulatory considerations for novel gene therapy products: a review of the process leading to the first clinical lentiviral vector. Hum Gene Ther. 2005;16(1):17–25. doi:10.1089/hum.2005.16.1715703485
   PubMed Web of Science ®Google Scholar
• Li M, Shen J, Wu X, et al. Downregulated expression of hepatoma-derived growth factor (HDGF) reduces gallbladder cancer cell proliferation and invasion. Med Oncol. 2013;30(2):587. doi:10.1007/s12032-013-0587-723609195
   PubMed Web of Science ®Google Scholar
• Mao J, Xu Z, Fang Y, et al. Hepatoma-derived growth factor involved in the carcinogenesis of gastric epithelial cells through promotion of cell proliferation by Erk1/2 activation. Cancer Sci. 2008;99(11):2120–2127. doi:10.1111/j.1349-7006.2008.00928.x18823380
   PubMed Web of Science ®Google Scholar
• Zhang A, Long W, Guo Z, et al. Downregulation of hepatoma-derived growth factor suppresses the malignant phenotype of U87 human glioma cells. Oncol Rep. 2012;28(1):62–68. doi:10.3892/or.2012.176822576797
   PubMed Web of Science ®Google Scholar
• Guo Z, He Y, Wang S, et al. Various effects of hepatoma-derived growth factor on cell growth, migration and invasion of breast cancer and prostate cancer cells. Oncol Rep. 2011;26(2):511–517. doi:10.3892/or.2011.129521567096
   PubMed Web of Science ®Google Scholar
• Jayachandran A, Dhungel B, Steel JC. Epithelial-to-mesenchymal plasticity of cancer stem cells: therapeutic targets in hepatocellular carcinoma. J Hematol Oncol. 2016;9(1):74. doi:10.1186/s13045-016-0307-927578206
   PubMed Web of Science ®Google Scholar
• Bindels EM, Vermey M, de Both NJ, et al. Influence of the microenvironment on invasiveness of human bladder carcinoma cell lines. Virchows Arch. 2001;439(4):552–559.11710643
   PubMed Web of Science ®Google Scholar
• Sun Y, Cheng MK, Griffiths TR, et al. Inhibition of STAT signalling in bladder cancer by diindolylmethane: relevance to cell adhesion, migration and proliferation. Curr Cancer Drug Targets. 2013;13(1):57–68.22920439
   PubMed Web of Science ®Google Scholar
• Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature. 2001;411(6835):342–348. doi:10.1038/3507721311357141
   PubMed Web of Science ®Google Scholar
• Yang Y, Li H, Zhang F, et al. Clinical and biological significance of hepatoma-derived growth factor in Ewing’s sarcoma. J Pathol. 2013;231(3):323–334. doi:10.1002/path.424123878072
   PubMed Web of Science ®Google Scholar
• Hsu SS, Chen CH, Liu GS, et al. Tumorigenesis and prognostic role of hepatoma-derived growth factor in human gliomas. J Neurooncol. 2012;107(1):101–109. doi:10.1007/s11060-011-0733-z22037800
   PubMed Web of Science ®Google Scholar
• Enomoto H, Nakamura H, Liu W, et al. Down-regulation of HDGF inhibits the growth of hepatocellular carcinoma cells in vitro and in vivo. Anticancer Res. 2015;35(12):6475–6479.26637859
   PubMed Web of Science ®Google Scholar
• Zhou Y, Zhou N, Fang W, et al. Overexpressed HDGF as an independent prognostic factor is involved in poor prognosis in Chinese patients with liver cancer. Diagn Pathol. 2010;5:58. doi:10.1186/1746-1596-5-5820846397
   PubMed Web of Science ®Google Scholar
• Ren H, Chu Z, Mao L. Antibodies targeting hepatoma-derived growth factor as a novel strategy in treating lung cancer. Mol Cancer Ther. 2009;8(5):1106–1112. doi:10.1158/1535-7163.MCT-08-077919435872
   PubMed Web of Science ®Google Scholar
• Brown DC, Gatter KC. Ki67 protein: the immaculate deception? Histopathology. 2002;40(1):2–11.11903593
   PubMed Web of Science ®Google Scholar
• Kumar A, Priyamvada S, Soni V. et al. Angiotensin II inhibits P-glycoprotein in intestinal epithelial cells. Acta Physiol (Oxf). 2019;e13332. doi:10.1111/apha.1333231177627
   PubMed Web of Science ®Google Scholar
• Wu XL, Wang LK, Yang DD, et al. Effects of Glut1 gene silencing on proliferation, differentiation, and apoptosis of colorectal cancer cells by targeting the TGF-beta/PI3K-AKT-mTOR signaling pathway. J Cell Biochem. 2018;119(2):2356–2367. doi:10.1002/jcb.2639928884839
   PubMed Web of Science ®Google Scholar
• Ciruelos Gil EM. Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer. Cancer Treat Rev. 2014;40(7):862–871. doi:10.1016/j.ctrv.2014.03.00424774538
   PubMed Web of Science ®Google Scholar
• Yan G, Ru Y, Wu K, et al. GOLM1 promotes prostate cancer progression through activating PI3K-AKT-mTOR signaling. Prostate. 2018;78(3):166–177. doi:10.1002/pros.2346129181846
   PubMed Web of Science ®Google Scholar